Form 8-K - Current report:
SEC Accession No. 0001193125-24-251698
Filing Date
2024-11-06
Accepted
2024-11-06 07:35:00
Documents
17
Period of Report
2024-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d904706d8k.htm   iXBRL 8-K 26609
2 EX-99.1 d904706dex991.htm EX-99.1 200804
6 GRAPHIC g904706dsp5.jpg GRAPHIC 11029
7 GRAPHIC g904706dsp5a.jpg GRAPHIC 1964
8 GRAPHIC g904706g1105042345827.jpg GRAPHIC 5866
  Complete submission text file 0001193125-24-251698.txt   397043

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20241106.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20241106_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20241106_pre.xml EX-101.PRE 10816
20 EXTRACTED XBRL INSTANCE DOCUMENT d904706d8k_htm.xml XML 3557
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 241429255
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)